Evidence map›Paper›PMID 36567978›Full record

ArticlePathology oncology research : POR2022

Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer.

Attila Paszt, Aurel Ottlakan, Szabolcs Abraham, Zsolt Simonka, Marton Vas, Aniko Maraz, Zoltan Szepes, Laszlo Tiszlavicz, Tibor Nyari, Judit Olah and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Attila PasztDepartment of Surgery, University of Szeged, Szeged, Hungary.
Aurel OttlakanDepartment of Surgery, University of Szeged, Szeged, Hungary.
Szabolcs AbrahamDepartment of Surgery, University of Szeged, Szeged, Hungary.
Zsolt SimonkaDepartment of Surgery, University of Szeged, Szeged, Hungary.
Marton VasDepartment of Surgery, University of Szeged, Szeged, Hungary.
Aniko MarazDepartment of Oncotherapy, University of Szeged, Szeged, Hungary.
Zoltan Szepes1st Department of Internal Medicine, University of Szeged, Szeged, Hungary.
Laszlo TiszlaviczDepartment of Pathology, University of Szeged, Szeged, Hungary.
Tibor NyariDepartment of Medical Physics and Informatics, University of Szeged, Szeged, Hungary.
Judit OlahDepartment of Oncotherapy, University of Szeged, Szeged, Hungary.
Gyorgy LazarDepartment of Surgery, University of Szeged, Szeged, Hungary.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoadjuvant TherapyRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyDeoxycytidineDiarrheaFluorouracilHumansNeoplasm StagingRetrospective StudiesTreatment OutcomeCapecitabineDeoxycytidineFluorouraciladvanced rectal cancercapecitabinechemoradiotherapyneoadjuvant treatmentsurgery

Identifiers

PMID36567978
PMCPMC9773127
OpenAlexW4311865395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.